

Supplementary Appendix

HIV and risk of COVID-19 death:

a population cohort study from the Western Cape Province, South Africa.

Table of Contents

1. Enumeration of different health conditions from the Western Cape Provincial Health Data Centre	1
Supplementary Table 1.....	2
2. Calculation of the Standardized Mortality Ratios (SMR) and population attributable fractions	3
3. Supplementary Results	5
Supplementary Table 2.....	5
Supplementary Table 3a.....	6
Supplementary Table 3b	7
Supplementary Table 4.....	7
Supplementary Table 5.....	10
4. Quantitative bias analysis to assess potential confounding of HIV and COVID-19 death association by obesity	12
Supplementary Table 7.....	15
Supplementary Table 8.....	17
5. List of contributing authors	17

1. Enumeration of different health conditions from the Western Cape Provincial Health Data Centre

The Western Cape Provincial Health Data Centre (WCPHDC) consolidates administrative, laboratory, and pharmacy data from routine electronic clinical information systems used in all public sector health facilities with linkage through a unique patient identifier. Multiple data sources are triangulated to enumerate health conditions such as diabetes mellitus (“diabetes”), hypertension, tuberculosis and HIV, with either high or moderate certainty evidence assigned for each inferred condition as outlined in Supplementary Table 1. For the main analysis we used conditions with high or moderate certainty evidence and restricted to conditions with high certainty evidence in a sensitivity analysis.

Supplementary Table 1

Summary of evidences used to infer different comorbidities in the Western Cape Provincial Health Data Centre with high or moderate certainty.

Inferred conditions	High certainty				Moderate		
	Laboratory tests	Drugs dispensed	Procedure or ICD-10 codes	Other evidences	Laboratory tests	Drugs dispensed	Procedure or ICD-10 codes
HIV	HIV-RNA viral load or positive HIV-RNA PCR or HIV genotypic resistance assay or positive HIV ELISA	valid combination antiretroviral therapy for >2 months		registered in HIV electronic chronic disease management system	CD4 count or positive rapid HIV test	2 antiretrovirals dispensed on same day in adult	HIV ICD-10 code (B20)
Tuberculosis	positive GeneXpert or line probe assay or microscopy, culture & microbiology	tuberculosis treatment regimen	tuberculosis ICD-10 code (A15)	admitted in tuberculosis hospital; registered in tuberculosis electronic chronic disease management system			
Diabetes Mellitus	HbA1c > 6.5% or oral glucose tolerance test >11.1mmol/l	diabetes treatment	diabetes ICD-10 code (E10/E11)		fasting blood glucose >7.0mmol/l, random blood glucose >11.0mmol/l		
Hypertension		hydrochlorothiazide					
Chronic obstructive pulmonary disease /asthma		β_2 agonists e.g. salbutamol; rimiterol					
Chronic Kidney Disease	2 consecutive eGFR measures <60ml/minute/1.73m ² , >90 days apart	transplant medication	procedure code for kidney transplant		tissue typing prior to dialysis or transplant		

ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision; eGFR estimated glomerular filtration rate

2. Calculation of the Standardized Mortality Ratios (SMR) and population attributable fractions

The calculation of the standardized mortality ratio follows standard methods.¹ We define the following symbols:

$q_{g,x}$ is the COVID-19 mortality rate in HIV-negative individuals of sex g , aged x .

$a_{g,x}$ is the COVID-19 mortality rate in HIV-positive individuals of sex g , aged x .

$N_{g,x}$ is the number of HIV-negative individuals of sex g , aged x .

$H_{g,x}$ is the number of HIV-positive individuals of sex g , aged x .

We further define D_H to be the total number of COVID-19 deaths in HIV-positive individuals:

$$D_H = \sum_g \sum_x H_{g,x} a_{g,x}$$

Similarly, we define D_T to be the total number of COVID-19 deaths (in both HIV-positive and HIV-negative individuals):

$$D_T = \sum_g \sum_x N_{g,x} q_{g,x} + H_{g,x} a_{g,x}$$

Estimates of the numbers of HIV-negative and HIV-positive individuals in 2020, by age and sex ($N_{g,x}$ and $H_{g,x}$), are taken from the Thembisa model for the Western Cape (version 4.3).² Thembisa is a combined demographic and HIV model, developed for South Africa, and is the main model on which UNAIDS estimates for South Africa are based. The model has been calibrated to each province in South Africa, based on fitting to age-specific HIV prevalence data from household surveys and antenatal clinic surveys.³ The age-specific COVID-19 mortality rates are estimated by dividing the recorded numbers of deaths at each age and sex by the corresponding Thembisa estimate of the population size.

The standardized mortality ratio (SMR) is defined as the ratio of the actual number of COVID-19 deaths in the HIV-positive population to the number of COVID-19 deaths that would be expected in the HIV-positive population if their COVID-19 mortality rates were the same as in the negative population (i.e. replacing $a_{g,x}$ with $q_{g,x}$):

$$SMR = \frac{D_H}{\sum_g \sum_x H_{g,x} q_{g,x}}$$

The population attributable fraction (PAF) is defined as the fraction of COVID-19 deaths that are attributable HIV. This is not the same as the fraction of deaths that occur in HIV-positive individuals because some of the COVID-19 deaths in HIV-positive individuals would have occurred even if they were HIV-negative (i.e. we are interested only in the excess mortality risk in HIV-positive individuals compared to HIV-negative individuals). Mathematically,

$$PAF = \frac{\sum_g \sum_x H_{g,x} (a_{g,x} - q_{g,x})}{D_T} = \frac{D_H - \sum_g \sum_x H_{g,x} q_{g,x}}{D_T} = \frac{D_H}{D_T} \left(1 - \frac{1}{SMR} \right)$$

3. Supplementary Results

Supplementary Table 2

Characteristics of Western Cape “active patients” in public sector ≥ 20 years of age (public sector health care visit in last 3 years before March 1, 2020) according to COVID-19 outcome using only high certainty evidence to determine comorbidities.

	No diagnosed COVID-19 n=3,436,810	COVID-19 not deceased n=21,679	COVID-19 deceased n=625
Sex			
female	1,983,495 (58%)	14,912 (69%)	340 (54%)
male	1,454,315 (42%)	6,767 (31%)	285 (46%)
Age			
20-39 years	1,913,786 (56%)	11,640 (54%)	46 (7%)
40-49 years	604,976 (18%)	4,515 (21%)	63 (10%)
50-59 years	447,739 (13%)	3,227 (15%)	162 (26%)
60-69 years	276,082 (8%)	1,423 (7%)	178 (28%)
≥ 70 years	194,227 (6%)	874 (4%)	176 (28%)
Diabetes			
none	3,177,659 (92%)	18,616 (86%)	256 (41%)
diabetes HbA1c <7%	44,776 (1%)	482 (2%)	58 (9%)
diabetes HbA1c 7 - 8.9%	47,199 (1%)	582 (3%)	94 (15%)
diabetes HbA1c $\geq 9\%$	65,629 (2%)	1,086 (5%)	158 (25%)
diabetes no HbA1c measurement	101,547 (3%)	913 (4%)	59 (9%)
Other non-communicable diseases			
hypertension	563,658 (16%)	4,907 (23%)	362 (58%)
chronic kidney disease	61,557 (2%)	493 (2%)	111 (18%)
chronic pulmonary disease / asthma	192,494 (6%)	1,576 (7%)	84 (13%)
Tuberculosis			
never tuberculosis	3,104,459 (90%)	19,664 (91%)	512 (82%)
previous tuberculosis	281,198 (8%)	1,698 (8%)	87 (14%)
current tuberculosis	51,453 (2%)	317 (1%)	26 (4%)
HIV			
negative	2,963,391 (86%)	18,136 (84%)	519 (83%)
positive	473,419 (16%)	3,543 (16%)	106 (17%)
VL <1000 copies/ml (last 15 mo) & ART script (last 6 mo)	240,029 (51%)	2,314 (66%)	71 (67%)
VL <1000 copies/ml (2yr to 15 mo prior) OR ART script (last 6 mo) & VL <1000 copies/ml > 2yr prior	68,865 (15%)	409 (12%)	11 (10%)
VL ≥ 1000 copies/ml (last 15 mo) or CD4 <200 cells/ μ l (last 18 mo)	37,767 (8%)	203 (6%)	11 (10%)
No VL (last 15 mo); CD4 ≥ 200 cells/ μ l or unknown (last 18 mo)	126,758 (27%)	599 (17%)	13 (12%)

*Cases analysis limited to cases diagnosed before 1 June 2020 when testing criteria changed with public sector tests being limited to patients >55 year of age or with comorbidities; Note: Column percentages may add up to >100% due to rounding; HbA1c glycosylated haemoglobin; VL viral load; mo month; yr year; ART antiretroviral therapy

Supplementary Table 3a

Current tuberculosis disease in Western Cape “active patients” in public sector ≥ 20 years of age (public sector health care visit in last 3 years before March 1, 2020) according to HIV status and COVID-19 outcome.

	Public sector patients with HIV			Public sector patients without HIV		
	No diagnosed COVID-19 n=536,574	COVID-19 not deceased n=3,863	COVID-19 deceased n=115	No diagnosed COVID-19 n=2,902,050	COVID-19 not deceased n=17,820	COVID-19 deceased n=510
No tuberculosis						
n	512,217	3,691	99	2,872,155	17,675	500
%	95.5	95.6	86.1	99.0	99.2	98.0
Tuberculosis intensive phase (rifampicin sensitive)						
n	8,576	104	11	10,269	83	7
%	2.0	3.0	10	0.4	0.5	1.4
Tuberculosis intensive phase (rifampicin resistant)						
n	678	7	3	525	4	3
%	0.1	0.2	2.6	0.0	0.0	0.6
Tuberculosis continuation (rifampicin sensitive/resistant)						
n	15,103	61	2	19,101	58	0
%	2.8	1.6	1.7	0.7	0.3	0.0

*Tuberculosis considered intensive phase if diagnosed <3 months previously (rifampicin sensitive) or <6 months previously (rifampicin resistant). Patients were considered to have “current tuberculosis” if first evidence of tuberculosis episode was between March 1, 2019 and study closure (June 9, 2020) and, in COVID-19 cases, <30 days after COVID-19 diagnosis date. All tuberculosis diagnoses after March 1, 2020 in COVID-19 cases were <30 days after date of COVID-19 diagnosis.

Supplementary Table 3b

Multivariate hazard ratios (HRs) and 95% confidence intervals (CI) for associations with COVID-19 death from Cox-proportional hazards models among all “active patients” in the public sector ≥ 20 years of age (public sector health visit in last 3 years before March 1, 2020) (n=3,460,932). Current tuberculosis is categorized as rifampicin sensitive or resistant and separated into intensive and continuation phases of treatment.

	Adjusted HR	95% CI	p-value
Sex			
female	Ref		
male	1.45	1.24; 1.70	<0.001
Age			
20-39 years	Ref		
40-49 years	2.84	1.93; 4.18	<0.001
50-59 years	7.85	5.56; 11.08	<0.001
60-69 years	11.64	8.18; 16.57	<0.001
≥ 70 years	16.96	11.81; 24.35	<0.001
Diabetes			
none	Ref		
diabetes HbA1c <7%	5.34	3.94; 7.23	<0.001
diabetes HbA1c 7 - 8.9%	8.51	6.59; 11.0	<0.001
diabetes HbA1c $\geq 9\%$	11.99	9.63; 14.92	<0.001
diabetes no HbA1c measurement	2.91	2.18; 3.89	<0.001
Other non-communicable diseases			
hypertension	1.31	1.09; 1.57	0.004
chronic kidney disease	0.92	0.73; 1.16	0.494
chronic pulmonary disease / asthma	1.86	1.49; 2.32	<0.001
Tuberculosis			
never tuberculosis	Ref		
tuberculosis intensive phase (rifampicin sensitive)*	5.54	3.44; 8.93	<0.001
tuberculosis intensive phase (rifampicin resistant)*	26.54	11.79; 59.75	<0.001
tuberculosis continuation phase (rifampicin sensitive/resistant)	0.33	0.08; 1.31	0.115
previous tuberculosis	1.49	1.17; 1.91	0.001
HIV			
negative	Ref		
positive	2.14	1.70; 2.70	<0.001

*Tuberculosis considered intensive phase if diagnosed <3 months previously (rifampicin sensitive) or <6 months previously (rifampicin resistant). Patients were considered to have “current tuberculosis” if first evidence of tuberculosis episode was between March 1, 2019 and study closure (June 9, 2020) and, in COVID-19 cases, <30 days after COVID-19 diagnosis date. All tuberculosis diagnoses after March 1, 2020 in COVID-19 cases were <30 days after date of COVID-19 diagnosis.
HbA1c glycosylated haemoglobin; HR hazard ratio; CI confidence interval

Supplementary Table 4

Multivariate hazard ratios (HRs) and 95% confidence intervals (CI) for associations with COVID-19 death from Cox-proportional hazards models among all “active patients” in public sector (age ≥ 20 years with a public sector health visit in the last 3 years before March 1, 2020) (n=3,460,932). Sensitivity analyses were conducted as follows: (i) as per main analysis but not adjusted for location; (ii) as per main analysis but including follow up through June 16, 2020; (iii) with competing risks regression; (iv) considering only comorbidities inferred with high certainty evidence (n= 3,459,114).

Description of data used in analysis	Not adjusted for location, censored on 9 June 2020 due to 7day lag in death reporting			Adjusted for location, all follow-up through 16 June 2020			Adjusted for location, censored on 9 June 2020 due to 7day lag in death reporting			Adjusted for location, censored on 9 June 2020 due to 7day lag in death reporting		
Certainty of evidence for comorbidities	All certainty			All certainty			All certainty			High certainty		
Analysis method	Cox-proportional hazards			Cox-proportional hazards			Competing risks (CR) regression with non-COVID-19 death as CR			Cox-proportional hazards		
	Adjusted HR	95% CI	p-value	Adjusted HR	95% CI	p-value	Adjusted SHR	95% CI	p-value	Adjusted HR	95% CI	p-value
Sex												
female	Ref									Ref		
male	1.41	1.20; 1.65	<0.001	1.53	1.33; 1.75	<0.001	1.45	1.23; 1.70	<0.001	1.46	1.24; 1.71	<0.001
Age												
20-39 years												
40-49 years	2.67	1.82; 3.92	<0.001	3.21	2.32; 4.45	<0.001	2.83	1.92; 4.17	<0.001	2.83	1.93; 4.16	<0.001
50-59 years	7.12	5.05; 10.05	<0.001	7.59	5.63; 10.21	<0.001	7.78	5.47; 11.06	<0.001	7.83	5.55; 11.05	<0.001
60-69 years	10.69	7.51; 15.2	<0.001	10.89	8.03; 14.78	<0.001	11.51	7.97; 16.62	<0.001	11.62	8.17; 16.54	<0.001
≥70 years	15.35	10.69; 22.02	<0.001	15.66	11.45; 21.42	<0.001	16.72	11.38; 24.56	<0.001	16.97	11.82; 24.37	<0.001
Diabetes												
none												
diabetes HbA1c <7%	5.25	3.88; 7.11	<0.001	4.71	3.59; 6.19	<0.001	5.35	3.88; 7.37	<0.001	5.29	3.91; 7.17	<0.001
diabetes HbA1c 7 - 8.9%	8.57	6.64; 11.07	<0.001	8.00	6.39; 10.02	<0.001	8.50	6.44; 11.22	<0.001	8.36	6.47; 10.79	<0.001
diabetes HbA1c ≥9%	12.53	10.08; 15.58	<0.001	11.70	9.69; 14.14	<0.001	12.03	9.47; 15.28	<0.001	11.92	9.59; 14.81	<0.001
diabetes no HbA1c measurement	3.07	2.3; 4.1	<0.001	2.88	2.24; 3.70	<0.001	2.92	2.15; 3.96	<0.001	2.78	2.07; 3.73	<0.001
Other non-communicable diseases												
hypertension	1.49	1.24; 1.78	<0.001	1.30	1.11; 1.52	<0.001	1.31	1.08; 1.59	0.007	1.31	1.09; 1.57	0.004
chronic kidney disease	1.93	1.54; 2.41	<0.001	1.89	1.56; 2.30	<0.001	1.85	1.45; 2.36	<0.001	1.87	1.50; 2.34	<0.001
chronic pulmonary disease / asthma	0.94	0.75; 1.19	0.631	1.08	0.89; 1.32	0.423	0.92	0.73; 1.17	0.498	0.94	0.74; 1.18	0.573
Tuberculosis												
never tuberculosis												
previous tuberculosis	1.53	1.2; 1.95	<0.001	1.46	1.18; 1.81	<0.001	1.51	1.18; 1.94	0.001	1.45	1.13; 1.86	0.004
current tuberculosis	2.68	1.79; 4	0.001	2.67	1.88; 3.80	<0.001	2.64	1.78; 3.91	<0.001	2.42	1.57; 3.74	<0.001
HIV												
negative												
positive	2.62	2.09; 3.29	<0.001	1.94	1.58; 2.39	<0.001	2.13	1.69; 2.70	<0.001	2.26	1.78; 2.88	<0.001
VL <1000 copies/ml (last 15 mo) & ART script (last 6 mo) [§]										2.62	1.99; 3.45	<0.001
VL <1000 copies/ml (2yr to 15 mo prior) or ART script (last 6 mo) & VL <1000 copies/ml >2yr prior										1.77	0.97; 3.26	0.064
VL ≥ 1000 copies/ml (last 15 mo) or CD4 <200 cells/μl (last 18 mo)										3.33	1.78; 6.24	<0.001
No VL (last 15 mo); CD4 ≥200 cells/μl or unknown (last 18 mo)										1.31	0.75; 2.30	0.345

[§]Reference category for hazard ratio is HIV negative; model adjusted for all other variables listed in this table in a different model that included the listed categories of HIV viral load and immune suppression instead of the binary variable HIV positive vs negative; the effect of the other variables on mortality was similar in this model;
CR competing risks; HR hazard ratio; SHR sub-distribution hazard ratio; CI confidence interval; HbA1c glycosylated haemoglobin; VL viral load; mo month(s); yr year(s); ART antiretroviral therapy

Supplementary Table 5

Multivariate hazard ratios (HRs) and 95% confidence intervals (CI) for associations with COVID-19 death from Cox-proportional hazards models among all adult COVID-19 cases diagnosed through to study closure (June 9, 2020) including period after June 1, 2020 when testing criteria changed (n=19,868).

Description of data used in analysis	Including all COVID-19 cases diagnosed until study closure (9 June 2020)		
	All certainty		
Certainty of evidence for comorbidities	Adjusted HR	95% CI	p-value
Sex			
female	Ref		
male	1.47	1.25; 1.72	<0.001
Age			
20-39 years			
40-49 years	2.70	1.83; 3.98	<0.001
50-59 years	8.72	6.17; 12.31	<0.001
60-69 years	19.05	13.37; 27.13	<0.001
≥70 years	31.43	21.93; 45.05	<0.001
Diabetes			
none			
diabetes HbA1c <7%	2.54	1.89; 3.43	<0.001
diabetes HbA1c 7 - 8.9%	3.48	2.70; 4.48	<0.001
diabetes HbA1c ≥9%	3.96	3.19; 4.91	<0.001
diabetes no HbA1c measurement	2.07	1.55; 2.76	<0.001
Other non-communicable diseases			
hypertension	1.07	0.89; 1.27	0.488
chronic kidney disease	1.81	1.45; 2.25	<0.001
chronic pulmonary disease / asthma	0.83	0.66; 1.05	0.125
Tuberculosis			
never tuberculosis			
previous tuberculosis	1.53	1.20; 1.95	0.001
current tuberculosis	1.78	1.19; 2.66	0.005
HIV			
negative			
positive	1.75	1.40; 2.19	<0.001
VL <1000 copies/ml (last 15 mo) & ART script (last 6 mo) [§]	1.75	1.34; 2.29	<0.001
VL <1000 copies/ml (2yr to 15 mo prior)	1.59	0.87; 2.92	0.135
OR ART script (last 6 mo) & VL <1000 copies/ml >2yr prior			
VL ≥ 1000 copies/ml (last 15 mo) or CD4 <200 cells/μl (last 18 mo)	3.80	2.07; 6.95	<0.001
No VL (last 15 mo); CD4 ≥200 cells/μl or unknown (last 18 mo)	1.54	1.01; 2.33	0.042
ART in PLWH with script issued in last 12 months[‡]			
abacavir or zidovudine	Ref		
tenofovir	0.49	0.28; 0.86	0.0121
efavirenz	Ref		
lopinavir	0.76	0.33; 1.77	0.5271
atazanavir	0.76	0.23; 2.51	0.6540
dolutegravir	0.73	0.25; 2.15	0.5732

[§]Reference category is HIV negative; adjusted for all other variables listed in this table in a different model that included the listed categories of HIV viral load, CD4 count and antiretroviral therapy instead of the binary variable HIV positive vs negative; the effect of the other variables on mortality was similar in this model and are not shown; [‡]Restricted to patients with documented antiretrovirals dispensed in the last 15 months, adjusted for all other variables listed in this table in a different model that included the relevant antiretrovirals; the effect of the other variables on mortality was similar in this model and are not shown; HR hazard ratio; CI confidence interval; HbA1c glycosylated haemoglobin.

Supplementary Table 6

Multivariate hazard ratios (HRs) and 95% confidence intervals (CI) for associations with COVID-19 death from Cox-proportional hazards models among all adult COVID-19 cases diagnosed before June 1, 2020 with current tuberculosis categorized as rifampicin sensitive or resistant and separated into intensive and continuation phase (n=15,203).


Description of data used in analysis	Limited to cases diagnosed before 1 June 2020 when testing criteria changed; rifampicin sensitive vs resistant tuberculosis and intensive/continuation phases separated		
	All certainty		
Certainty of evidence for comorbidities	Adjusted HR	95% CI	p-value
Sex			
female	Ref		
male	1.48	1.26; 1.74	<0.001
Age			
20-39 years			
40-49 years	2.68	1.82; 3.96	<0.001
50-59 years	8.68	6.14; 12.25	<0.001
60-69 years	18.84	13.22; 26.85	<0.001
≥70 years	31.14	21.73; 44.63	<0.001
Diabetes			
none			
diabetes HbA1c <7%	2.54	1.88; 3.42	<0.001
diabetes HbA1c 7 - 8.9%	3.51	2.72; 4.53	<0.001
diabetes HbA1c ≥9%	3.93	3.17; 4.87	<0.001
diabetes no HbA1c measurement	2.08	1.56; 2.78	<0.001
Other non-communicable diseases			
hypertension	1.06	0.89; 1.27	0.518
chronic kidney disease	1.81	1.45; 2.25	<0.001
chronic pulmonary disease / asthma	0.85	0.67; 1.07	0.172
Tuberculosis			
never tuberculosis			
previous tuberculosis	1.48	1.16; 1.89	0.001
tuberculosis intensive phase (rifampicin sensitive)*	1.99	1.20; 3.30	0.008
tuberculosis intensive phase (rifampicin resistant)*	5.55	2.25; 13.68	<0.001
tuberculosis continuation phase (rifampicin sensitive/resistant)	0.88	0.36; 2.14	0.783
HIV			
negative			
positive	1.78	1.42; 2.22	<0.001

*Tuberculosis considered intensive phase if diagnosed <3 months previously (rifampicin sensitive) or <6 months previously (rifampicin resistant). Patients were considered to have "current tuberculosis" if first evidence of tuberculosis episode was between March 1, 2019 and study closure (June 1, 2020) (COVID-19 non-cases) and <30 days after COVID-19 diagnosis date (COVID-19 cases). All tuberculosis diagnoses after March 1, 2020 in COVID-19 cases were <30 days after date of COVID-19 diagnosis.

HR hazard ratio; CI confidence interval; HbA1c glycosylated haemoglobin.

4. Quantitative bias analysis to assess potential confounding of HIV and COVID-19 death association by obesity

The objective of the quantitative bias analysis is to assess the extent to which the measured association between HIV and COVID-19 mortality might be biased due to not controlling for obesity (a variable that is not routinely measured in the Western Cape Provincial Health Data Centre). Supplementary Figure 1 illustrates the conceptual model. We distinguish between untreated and treated HIV for the purpose of this analysis, as the prevalence of obesity is likely to be different in treated and untreated HIV-positive individuals, which in turn has implications for the extent of the bias if we do not control for obesity.



Supplementary Figure 1: Potential causal pathways linking HIV and COVID-19 mortality

We adopt a Bayesian approach to quantitative bias analysis, which involves specifying prior distributions to represent the plausible ranges of uncertainty around the key parameters in the above model.⁴ Using notation similar to that in Greenland,⁵ we define the parameters in which we are interested as follows:

- $\Omega(U)$ is the odds of obesity in the HIV-negative population.

- $\Omega(T_1U)$ is the odds ratio for the association between untreated HIV and obesity.
- $\Omega(T_2U)$ is the odds ratio for the association between treated HIV and obesity.
- $\Omega(UY|T)$ is the odds ratio for the association between obesity and COVID-19 death, when controlling for HIV.
- $\Omega(T_1Y|U)$ is the odds ratio for the association between untreated HIV and COVID-19 mortality, when controlling for obesity.
- $\Omega(T_2Y|U)$ is the odds ratio for the association between treated HIV and COVID-19 mortality, when controlling for obesity.
- $\Omega(T_1Y)$ is the odds ratio for the association between untreated HIV and COVID-19 mortality, when not controlling for obesity.
- $\Omega(T_2Y)$ is the odds ratio for the association between untreated HIV and COVID-19 mortality, when not controlling for obesity.

We define B_1 as the bias due to not controlling for obesity when assessing the association between untreated HIV and COVID-19 mortality:

$$B_1 = \frac{\Omega(T_1Y)}{\Omega(T_1Y | U)}$$

When $\Omega(T_1Y|U)$ is unknown (as is the case here), the bias can instead be calculated using the following formula⁵:

$$B_1 = \frac{(\Omega(T_1U)\Omega(UY|T)\Omega(U) + 1)(\Omega(U) + 1)}{(\Omega(T_1U)\Omega(U) + 1)(\Omega(UY|T)\Omega(U) + 1)}$$

Substituting this estimate of B_1 into the previous equation allows us to estimate $\Omega(T_1Y|U)$.

Similarly, B_2 is defined as the bias due to not controlling for obesity when assessing the association between treated HIV and COVID-19 mortality, and is estimated in the same way.

The sections that follow describe the approaches to specifying prior distributions for each of the key parameters.

Odds of obesity in the HIV negative population ($\Omega(U)$)

We analysed data from the 2016 Demographic and Health Survey (DHS).⁶ In this survey, the prevalence of obesity (a BMI of 30 or higher) in HIV-negative adults (aged 15 or older) in the Western Cape was 35.3% (95% CI: 29.0-41.6%). If P is the prevalence of obesity, then the odds of obesity is $\Omega(U) = P/(1 - P)$. We assign a normal distribution to represent the uncertainty in P , with a mean of 35.3% and a standard deviation of 3.2% (to be consistent with the 95% confidence intervals around the survey estimate).

Association between HIV and obesity ($\Omega(T_1U)$ and $\Omega(T_2U)$)

We assessed the association between HIV and obesity using data from the 2016 DHS.⁶ We fitted a logistic regression model to the data collected for adults (ages 15 and older), controlling for age and sex. For the purpose of this analysis, individuals were classified as having treated HIV if they were HIV-positive and reported taking one or more antiretroviral drugs (this is likely to be an underestimate of the true ART uptake as many ART patients do not report being on treatment or else report not knowing their HIV status).⁷⁻¹⁰

Results are summarized in Supplementary Table 7. These results suggest that obesity is reduced in untreated HIV-positive individuals, and is further reduced in treated HIV-positive individuals (although the difference in odds of obesity between treated and untreated HIV is not statistically significant). These results may appear counter-intuitive, as previous cohort studies suggest that ART initiation leads to significant weight recovery.¹¹ However, the results are consistent with the results from another large South African survey in KwaZulu-

Natal, which found that in multivariable analysis, BMI was lower in untreated HIV-positive individuals than in HIV-negative individuals and that BMI was even lower in patients who were on ART.¹² Cohort studies typically compare BMI immediately prior to ART initiation (usually when patients already have advanced HIV) and BMI at longer ART durations, which may give a distorted sense of the average levels of weight loss in untreated HIV.

Supplementary Table 7

Factors associated with obesity in the 2016 Demographic and Health Survey

	Adjusted odds ratio (95% CI)
HIV status	
HIV-negative	1
HIV-positive, untreated	0.62 (0.53-0.73)
HIV-positive, treated	0.47 (0.37-0.61)
Sex	
Male	1
Female	5.56 (4.81-6.42)
Age group	
15-24	1
25-34	3.85 (3.12-4.74)
35-44	7.72 (6.20-9.61)
45-54	8.41 (6.75-10.48)
55-64	8.21 (6.54-10.29)
65+	5.36 (4.27-6.72)

To represent the uncertainty around $\Omega(T_1U)$ and $\Omega(T_2U)$, we use lognormal prior distributions with means and standard deviations matching the odds ratios in Table 1.

Association between obesity and COVID-19 mortality ($\Omega(UY|T)$)

A large study based on NHS data in the UK found that among COVID-19 cases, mortality was strongly associated with mortality, with the increase being modest for grade I obesity (aHR 1.27, 95% CI: 1.18-1.36), higher for grade II obesity (aHR 1.56, 95% CI: 1.41-1.73) and highest for grade III obesity (aHR 2.27, 95% CI: 1.99-2.58).¹³ In the South African 2016 DHS, the proportion of obese adults in each class was 55%, 26% and 19% respectively.

Applying these proportions to the odds ratios in the UK study, the weighted average odds ratio is 1.53. Although the UK study did not directly control for HIV, it did control for “immunosuppressive conditions” (unspecified), and controlling for HIV would probably not have changed the association between obesity and COVID-19 mortality given the low HIV prevalence in the UK.

We assign a lognormal prior distribution to represent the uncertainty around $\Omega(UY|T)$. The prior distribution has a mean of 1.53 (the same as the weighted average of the odds ratios in the UK study) and 2.5 and 97.5 percentiles of 1.39 and 1.69 respectively. These percentiles correspond to the weighted averages of the lower and upper confidence interval limits for the odds ratios quoted previously.

Monte Carlo analysis

We approximate $\Omega(T_1Y|U)$ and $\Omega(T_2Y|U)$ by randomly drawing 10,000 parameter combinations from the prior distributions specified previously, and substituting into the previous equations to solve for $\Omega(T_1Y|U)$ and $\Omega(T_2Y|U)$. We also randomly draw values from the estimates for $\Omega(T_1Y)$ and $\Omega(T_2Y)$ in Table 4 of the main paper (1.73 (95% CI: 1.10-2.71) and 1.60 (95% CI: 1.19-2.17) respectively), again using lognormal distributions. Table 2 summarizes the results of this Monte Carlo analysis. Controlling for obesity leads to a slight increase in the estimated strength of association between HIV and COVID-19 mortality, which is because the prevalence of obesity is lower in HIV-positive individuals than in HIV-negative individuals.

Supplementary Table 8

Bias due to not controlling for obesity

	Untreated HIV		Treated HIV	
	Symbol	Estimate	Symbol	Estimate
Bias due to not controlling for obesity	B_1	0.956 (0.937-0.973)	B_2	0.934 (0.909-0.958)
OR for association between HIV and COVID-19 mortality	$\Omega(T_1Y)$	1.73 (1.10-2.73)	$\Omega(T_2Y)$	1.60 (1.19-2.17)
OR for association between HIV and COVID-19 mortality, adjusted	$\Omega(T_1Y U)$	1.85 (1.14-2.84)	$\Omega(T_1Y U)$	1.74 (1.27-2.34)

5. List of contributing authors

Western Cape Government: Health

Health Impact Assessment Directorate: Andrew Boulle,^{1,2} Mary-Ann Davies,^{1,2} Hannah Hussey,^{1,3} Muzzammil Ismail,^{1,3} Erna Morden,^{1,3} Ziyanda Vundle,^{1,4} Virginia Zweigenthal^{1,3}

Metro and Rural Health Outbreak Response Team Leads: Hassan Mahomed,^{4,5} Masudah Paleker,^{4,5} David Pienaar,⁶ Yamanya Tembo^{3,6}

Communicable Disease Control sub-Directorate: Charlene Lawrence,⁷ Washiefa Isaacs,⁷ Hlengani Mathema^{7,8}

Provincial Health Data Centre: Derick Allen,² Taryn Allie,^{1,2} Jamy-Lee Bam,¹ Kasturi Buddiga,^{1,2} Pierre Dane,^{1,2} Alexa Heekes,^{1,2} Boitumelo Matlapeng,^{1,2} Themba Mutemaringa,^{1,2} Luckmore Muzarabani,^{1,2} Florence Phelanyane,^{1,2} Rory Pienaar,¹ Catherine Rode,^{1,2} Mariette Smith,^{1,2} Nicki Tiffin,^{1,2,9,10} Nesbert Zinyakatira^{1,3}

Health Programmes Directorate: Carol Cragg,¹¹ Frederick Marais,^{11,12} Vanessa Mudaly,^{3,11} Jacqueline Voget¹¹

Hospitals: George Hospital: Jody Davids,¹³ Francois Roodt,¹³ Nellis van Zyl Smit,¹³ Alda Vermeulen¹³

Groote Schuur Hospital: Gordon Audley,^{14,15} Peter Beckwith,^{14,15} Dirk Blom,^{14,15} Linda Boloko,^{14,15} Adam Boutall,^{14,16} Lydia Cairncross,^{14,16} Gregory Calligaro,^{14,15} Cecilia Coccia,^{14,15} Chadwin Corin,^{14,15} R Daruala,^{14,15} Joel Dave,^{14,15} Elsa De Bruyn,^{14,15} Martin De Villiers,^{14,15} Mimi Deetlefs,^{14,15} Siphon Dlamini,^{14,15} Thomas Du Toit,^{14,15} Silke Dyer,^{14,17} Wilhelm Endres,^{14,15} Tarin Europa,^{14,15} Graham Fieggan,^{14,16} Petro Frankenfeld,^{14,15} Elizabeth Gatley,^{14,15} Phindile Gina,^{14,15} Evashan Govender,^{14,15} Rochelle Grobler,^{14,15} MV Gule,^{14,15} Christoff Hanekom,^{14,15} Michael Held,^{14,15} Alana Heynes,^{14,15} Sabelo Hlatswayo,^{14,15} Bridget Hodgkinson,^{14,15} Shakeel Hoosain,^{14,15} Ashely Jacobs,^{14,15} Mariam Kahn,^{14,15} Thania Kahn,^{14,15} Riaasat Khan,^{14,15} Joubin Khan,^{14,15} Alicia Khwitshana,^{14,15} Sharita Kooverjee,^{14,15} Jean Jacque Kruger,^{14,15} R. Krogscheepers,^{14,15} Suzanne Kuhn,^{14,15} John Lazarus,^{14,16} Jacque Le Roux,^{14,15} Scott Lee Jones,^{14,15} Dion Levin,^{14,15} Gary Maartens,^{14,15} Thina Majola,^{14,15} Rodgers Manganyi,^{14,15} David Marais,^{14,15} Deborah Maughan,^{14,15} Simthandile Mazondwa,^{14,15} Luyanda Mbangwa,^{14,15} Nomonde Mbatani,^{14,15} Bulewa Mbena,^{14,15} Graeme Meintjes,^{14,15}

Marc Mendelson,^{14, 15} Ernst Moller,^{14, 15} Babalwa Ndebele,^{14, 15} Notbeko Ntusi,^{14, 15}
F Nyengane,^{14, 15} Tari Papavarnavas,^{14, 15} Peter Raubenheimer,^{14, 15} Gordon Robertson,^{14, 15}
Julius Rozmiarek,^{14, 15} A Sayed,^{14, 15} Hennie Sekhukhune,^{14, 15} Prasun Singh,^{14, 15}
Elsabe Smith,^{14, 15} Cari Stek,^{14, 15} Robert van den berg,^{14, 15} Le Roux Van der Merwe,^{14, 15}
Barbra Vermooten,^{14, 15} Gerrit Viljoen,^{14, 15} Santhuri Viranna,^{14, 15} Nana Vundla,^{14, 15}
Sean Wasserman,^{14, 15} Eddy Zitha^{14, 15}

Karl Bremer Hospital: De Villiers Basson,¹⁸ Sue Le Roux,¹⁸ Ethel Linden-Mars,¹⁸
Lizanne Victor,¹⁸ Mark Wates,¹⁸ Elbe Zwanepoel¹⁸

Khayelitsha District Hospital: Nabilah Ebrahim,¹⁹ Sa'ad Lahri,¹⁹ Ayanda Mnguni¹⁹

Mitchells Plain Hospital: Thomas Crede,²⁰ Martin de Man,^{20, 31} Katya Evans,^{20, 31}

Clint Hendrikse,^{20, 31} Jonathan Naude,²⁰ Moosa Parak,^{20, 31} Candice Van Koningsbruggen^{20, 31}

Tygerberg Hospital: Riezaah Abrahams,^{21, 22} Brian Allwood,^{21, 22} Christoffel Botha,^{21, 22}

Matthys Henndrik Botha,^{21, 23} Alistair Broadhurst,^{21, 22} Dirkie Claasen,^{21, 22} Che Daniel,^{21, 22}

Riyaadh Dawood,^{21, 22} Marie du Preez,^{21, 22} N Du Toit,^{21, 23} K Erasmus,^{21, 24}

Coenraad FN Koegelenberg,^{21, 22} Shiraaz Gabriel,^{21, 22} Susan Hugo,^{21, 22} Thabiet Jardine,^{21, 22}

Clint Johannes,^{21, 22} Sumanth Karamchand,^{21, 22} Usha Lalla,^{21, 22} Eduard Langenegger,^{21, 23}

Eize Louw,^{21, 22} Boitumelo Mashigo,^{21, 22} Nonte Mhlana,^{21, 22} Chizama Mngqazi,^{21, 22}

Ashley Moodley,^{21, 23} Desiree Moodley,^{21, 22} Saadiq Moolla,^{21, 22} Abdurasiet Mowlana,^{21, 22}

Andre Nortje,^{21, 22} SE Olivier,^{21, 23} Arifa Parker,^{21, 22} Chané Paulsen,^{21, 22}

Hans Prozesky,^{21, 23} Jacques Rood,^{21, 22} Tholakele Sabela,^{21, 22} Neshaad Schrueder,^{21, 22}

Sthembiso Sithole,^{21, 22} Nokwanda Sithole,^{21, 22} Jantjie J Taljaard,^{21, 22} Gideon Titus,^{21, 22}

TA Van Der Merwe,^{21, 23} Marije van Schalkwyk,^{21, 22} Luthando Vazi,^{21, 22}

Abraham J Viljoen,^{21, 22} Mogamat Yazied Chothia^{21, 22}

Emergency Medical Services: Lee Alan Wallis^{24, 31}

District Outbreak Response Teams: Mumtaz Abbass,²⁵ Juanita Arendse,²⁵ Rizqa Armien,²⁵

R Bailey,²⁵ Muideen Bello,²⁵ Rachel Carelse,²⁵ Sheron Forgas,²⁵ Nosi Kalawe,²⁵

Mariska Kotze,²⁵ Jonathan Lucas,²⁵ Juanita McClaughlin,²⁵ Melvin Moodley,¹

Kathleen Murie,²⁵ Leilah Najjaar,²⁵ Liesel Petersen,²⁵ James Porter,²⁵ Melanie Shaw,²⁵

Dusica Stapar,²⁵ Michelle Williams²⁵

City of Cape Town: Linda Aldum,²⁶ Natacha Berkowitz,²⁶ Raakhee Girran,²⁶ Kevin Lee,²⁶
Lenny Naidoo,²⁶ Caroline Neumuller²⁶

Outbreak Response Pod Team: Kim Anderson,² Kerrin Begg,³ Lisa Boerlage,³

Morna Cornell,² Renée de Waal,² Lilian Dudley,⁵ René English,⁵ Jonathan Euvrard,²

Pam Groenewald,²⁷ Nisha Jacob,³ Heather Jaspán,³² Emma Kalk,² Naomi Levitt,¹⁵

Thoko Malaba,³ Patience Nyakato,² Gabriela Patten,² Helen Schneider,²⁸

Maylene Shung King,³ Priscilla Tsondai,² James Van Duuren,³ Nienke van Schaik

National Institute for Communicable Diseases: Lucille Blumberg,⁸ Cheryl Cohen,⁸

Nelesh Govender,^{8, 29} Waasila Jassat⁸ Tendesayi Kufa,⁸ Kerrigan McCarthy⁸ Lynn Morris⁸

National Health Laboratory Service: Nei-yuan Hsiao,³⁰ Ruan Marais³⁰

Statistical and Analytic Support: Jon Ambler,⁹ Olina Ngwenya,⁹ Richard Osei-Yeboah,¹⁰

Leigh Johnson,² Reshma Kassanjee,² Tsaone Tamuhla¹⁰

Affiliations

- 1 Health Impact Assessment, Western Cape Government: Health
- 2 Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town
- 3 School of Public Health and Family Medicine, University of Cape Town
- 4 Division of Health Systems and Public Health, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University
- 5 Metro Health Services, Western Cape Government: Health
- 6 Rural Health Services, Western Cape Government: Health
- 7 Communicable Disease Sub-Directorate, Western Cape Government: Health
- 8 National Institute for Communicable Diseases, National Health Laboratory Service, South Africa
- 9 Wellcome Centre for Infectious Disease Research in Africa, University of Cape Town
- 10 Division of Computational Biology, University of Cape Town
- 11 Health Programmes Directorate,, Western Cape Government: Health
- 12 Faculty of Health Sciences, North West University
- 13 George Hospital, Western Cape Government: Health
- 14 Groote Schuur Hospital, Western Cape Government: Health
- 15 Department of Medicine, University of Cape Town
- 16 Department of Surgery, University of Cape Town
- 17 Department of Obstetrics and Gynaecology, University of Cape Town
- 18 Karl Bremer Hospital, Western Cape Government: Health
- 19 Khayelitsha District Hospital, Western Cape Government: Health
- 20 Mitchells Plain and Heideveld Hospitals, Western Cape Government: Health
- 21 Tygerberg Hospital, Western Cape Government: Health
- 22 Department of Medicine, Stellenbosch University
- 23 Department of Obstetrics and Gyneacology, Stellenbosch University
- 24 Emergency Medical Services, Western Cape Government:
- 26 City Health, Community Services and Health, City of Cape Town
- 27 South African Medical Research Council Burden of Disease Research Unit
- 28 School of Public Health, University of the Western Cape
- 29 School of Pathology, University of the Witwatersrand and School of Pathology, University of Cape Town
- 30 National Health Laboratory Service and Division of Virology, University of Cape Town
- 31 Division of Emergency Medicine, University of Cape Town
- 32 Division of Immunology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town

References

1. Armitage P. *Statistical Methods in Medical Research*. Oxford, United Kingdom: Blackwell; 1971.
2. Johnson LF, Dorrington RE. *Modelling the impact of HIV in South Africa's provinces: 2020 update*: Centre for Infectious Disease Epidemiology and Research, University of Cape Town; 2020. Available at: <https://www.thembisa.org/>. Accessed 26 June 2020.
3. Johnson LF, Dorrington RE, Moolla H. HIV epidemic drivers in South Africa: a model-based evaluation of factors accounting for inter-provincial differences in HIV prevalence and incidence trends. *South African Journal of HIV Medicine* 2017;18:a695.
4. Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. *International Journal of Epidemiology* 2014;43:1969-85.
5. Greenland S. Multiple-bias modelling for analysis of observational data. *J Roy Stat Soc A* 2005;168:267-306.
6. Department of Health, Statistics South Africa, South African Medical Research Council, ICF. *South Africa Demographic and Health Survey 2016*. Pretoria; 2019. Available at: <https://www.dhsprogram.com/pubs/pdf/FR337/FR337.pdf>. Accessed 19 March 2019.
7. Grobler A, Cawood C, Khanyile D, Puren A, Kharsany ABM. Progress of UNAIDS 90-90-90 targets in a district in KwaZulu-Natal, South Africa, with high HIV burden, in the HIPSS study: a household-based complex multilevel community survey. *Lancet HIV* 2017;4:e505-e13.
8. Johnson LF, Rehle TM, Jooste S, Bekker LG. Rates of HIV testing and diagnosis in South Africa, 2002-2012: successes and challenges. *AIDS* 2015;1401-9.
9. Rohr JK, Xavier Gomez-Olive F, Rosenberg M, et al. Performance of self-reported HIV status in determining true HIV status among older adults in rural South Africa: a validation study. *J Int AIDS Soc* 2017;20:21691.
10. Sandfort TGM, Dominguez K, Kayange N, et al. HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. *PloS ONE* 2019;14:e0217501.
11. Nduka CU, Uthman OA, Kimani PK, Stranges S. Body fat changes in people living with HIV on antiretroviral therapy. *AIDS Reviews* 2016;18:198-211.
12. Malaza A, Mossong J, Bärnighausen T, Newell ML. Hypertension and obesity in adults living in a high HIV prevalence rural area in South Africa. *PloS ONE* 2012;7:e47761.
13. Williamson E, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. *MedRxiv* 2020. Available at: <https://www.medrxiv.org/content/10.1101/2020.05.06.20092999v1>. Accessed 3 June 2020.